Literature DB >> 24072839

Acute liver injury secondary to sertraline.

Christopher F D Li Wai Suen1, Ray Boyapati, Ian Simpson, Anouk Dev.   

Abstract

Sertraline is widely prescribed to treat depression and anxiety disorders. However, hepatitis secondary to its use is a rare entity. We report the case of a 26-year-old woman in her 20th week of pregnancy presented with nausea, vomiting, malaise and dark urine. This occurred 6 months after sertraline 50 mg daily was started for the treatment of depression. Three weeks prior to her presentation, the dose of sertraline was increased to 100 mg daily. The patient's liver biochemical profile demonstrated increased transaminases. The biopsy of the liver showed lobular hepatitis, with a mild prominence of eosinophils, suggestive of a drug-induced or toxin-induced aetiology. Extensive biochemical work-up failed to show any other pathology to account for her hepatitis. Liver function tests normalised after cessation of sertraline, indicating a probable association between sertraline use and acute hepatocellular injury in our patient.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24072839      PMCID: PMC3794285          DOI: 10.1136/bcr-2013-201022

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  18 in total

1.  Acute liver damage possibly related to sertraline and venlafaxine ingestion.

Authors:  K Y Kim; W Hwang; R Narendran
Journal:  Ann Pharmacother       Date:  1999-03       Impact factor: 3.154

2.  Acute fatal hepatitis related to sertraline.

Authors:  L Fartoux-Heymann; C Hézode; E S Zafrani; D Dhumeaux; A Mallat
Journal:  J Hepatol       Date:  2001-11       Impact factor: 25.083

3.  Symptomatic liver injury probably related to sertraline.

Authors:  M L Hautekeete; I Colle; H van Vlierberghe; A Elewaut
Journal:  Gastroenterol Clin Biol       Date:  1998-03

4.  Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers.

Authors:  Heidi L Liston; C Lindsay DeVane; David W Boulton; Samuel C Risch; John S Markowitz; Juliet Goldman
Journal:  J Clin Psychopharmacol       Date:  2002-04       Impact factor: 3.153

5.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

6.  A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline.

Authors:  H Croft; E Settle; T Houser; S R Batey; R M Donahue; J A Ascher
Journal:  Clin Ther       Date:  1999-04       Impact factor: 3.393

Review 7.  Clinical pharmacokinetics of sertraline.

Authors:  C Lindsay DeVane; Heidi L Liston; John S Markowitz
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

8.  Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals.

Authors:  H Bagheri; F Michel; M Lapeyre-Mestre; E Lagier; J P Cambus; P Valdiguié; J L Montastruc
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

9.  Sertraline hepatotoxicity: report of a case and review of the literature.

Authors:  Fehmi Tabak; Feyza Gunduz; Veysel Tahan; Omur Tabak; Resat Ozaras
Journal:  Dig Dis Sci       Date:  2008-10-29       Impact factor: 3.199

10.  Fulminant chemical hepatitis possibly associated with donepezil and sertraline therapy.

Authors:  M M Verrico; D A Nace; A L Towers
Journal:  J Am Geriatr Soc       Date:  2000-12       Impact factor: 5.562

View more
  3 in total

1.  Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.

Authors:  Paola Nicoletti; Guruprasad P Aithal; Einar S Bjornsson; Raul J Andrade; Ashley Sawle; Marco Arrese; Huiman X Barnhart; Emmanuelle Bondon-Guitton; Paul H Hayashi; Fernando Bessone; Alfonso Carvajal; Ingolf Cascorbi; Elizabeth T Cirulli; Naga Chalasani; Anita Conforti; Sally A Coulthard; Mark J Daly; Christopher P Day; John F Dillon; Robert J Fontana; Jane I Grove; Pär Hallberg; Nelia Hernández; Luisa Ibáñez; Gerd A Kullak-Ublick; Tarja Laitinen; Dominique Larrey; M Isabel Lucena; Anke H Maitland-van der Zee; Jennifer H Martin; Mariam Molokhia; Munir Pirmohamed; Elizabeth E Powell; Shengying Qin; Jose Serrano; Camilla Stephens; Andrew Stolz; Mia Wadelius; Paul B Watkins; Aris Floratos; Yufeng Shen; Matthew R Nelson; Thomas J Urban; Ann K Daly
Journal:  Gastroenterology       Date:  2016-12-30       Impact factor: 22.682

2.  HBK-14 and HBK-15 Do Not Influence Blood Pressure, Lipid Profile, Glucose Level, or Liver Enzymes Activity after Chronic Treatment in Rats.

Authors:  Karolina Pytka; Monika Głuch-Lutwin; Joanna Knutelska; Magdalena Jakubczyk; Anna Waszkielewicz; Magdalena Kotańska
Journal:  PLoS One       Date:  2016-10-27       Impact factor: 3.240

Review 3.  Antidepressants- and antipsychotics-induced hepatotoxicity.

Authors:  Nevena Todorović Vukotić; Jelena Đorđević; Snežana Pejić; Neda Đorđević; Snežana B Pajović
Journal:  Arch Toxicol       Date:  2021-01-05       Impact factor: 5.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.